AT-193 is under clinical development by Azora Therapeutics and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData, Phase I drugs for Hidradenitis Suppurativa have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-193’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AT-193 overview

AT-193 is under development for the treatment of hidradenitis suppurativa and plaque psoriasis, psoriatic arthritis, atopic dermatitis and rare dermatological disorders. It is a small molecule. It is administered through topical route.

Azora Therapeutics overview

Azora Therapeutics operates within the pharmaceuticals and healthcare industry, specifically focusing on the therapy area of dermatology and unspecified dermatological disorders. It specializes in the research, development, and production of pharmaceutical products for the treatment of various unspecified dermatological disorders. The company is headquartered in Encino, California, the US.

For a complete picture of AT-193’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.